



### Number of metastatic sites < 2



### Number of metastatic sites $\geq 2$



**Supplementary Figure S4.** Survival difference stratified by the number of metastatic sites (< 2 vs.  $\geq 2$ ). (**a–c**) Progression-Free Survival (PFS), Overall Survival (OS) and Duration of Response (DOR) in the increased PD-1<sup>+</sup>CD8<sup>+</sup> T-cell group ( $n = 22$ ) and the decreased PD-1<sup>+</sup>CD8<sup>+</sup> T-cell group ( $n = 23$ ) among patients with fewer than two metastatic sites. (**d–f**) PFS, OS and DOR in the increased PD-1<sup>+</sup>CD8<sup>+</sup> T-cell group ( $n = 6$ ) and the decreased PD-1<sup>+</sup>CD8<sup>+</sup> T-cell group ( $n = 17$ ) among patients with more than two metastatic sites. The increased PD-1<sup>+</sup>CD8<sup>+</sup> T-cell group showed longer PFS, OS and DOR among patients with fewer than two metastatic sites. (PFS: 9.6 months vs. 7.9 months,  $p = 0.050$ ; OS: 26.4 months vs. 14.2 months,  $p = 0.011$ ; DOR: 11.6 vs. 6.8 months,  $p = 0.040$ )